• 2024
  Gnaien M, Maufrais C, Rebai Y, Kallel A, Ma L, Hamouda S, Khalsi F, Meftah K, Smaoui H, Khemiri M, Hadj Fredj S, Bachellier-Bassi S, Najjar I, Messaoud T, Boussetta K, Kallel K, Mardassi H, d'Enfert C, Bougnoux ME, Znaidi S, A gain-of-function mutation in zinc cluster transcription factor Rob1 Drives Candida albicans adaptive growth in the cystic fibrosis lung environment., PLoS Pathog 2024 Apr; 20(4): e1012154.
• 2021
  Najjar I, Motreff L, Ma L, Lemée L, Briolat V, Monot M, , How Did Institut Pasteur’s NGS Core Facility, Biomics, Manage the Coronavirus Disease 2019 Crisis?, J Biomol Tech 2021 07; 32(2): 50-56.
• 2020
  Esterre P, Ait-Saadi A, Arowas L, Chaouche S, Corre-Catelin N, Fanaud C, Laude H, Mellon V, Monceaux, V, Morizot G, Najjar I, Ottone C, Perlaza BL, Rimbault B, Sangari L, Ungeheuer, M-N, The ICAReB Platform: A Human Biobank for the Institut Pasteur and Beyond, Open Journal of Bioresources. 2020; 7: 1.
• 2013
  Tordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, Jaafari N, Schischmanoff O, Fagard R, Lagdas E, Kermarrec S, Ribardiere S, Botbol M, Fougerou C, Bronsard G, Vernay-Leconte J, Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives, Int J Mol Sci 2013 Oct;14(10):20508-42.
• 2013
  Casetti L, Martin-Lannerée S, Najjar I, Dusanter-Fourt I, [STAT5, a new therapeutic target against the relapse of chronic myelogenous leukemia?], Med Sci (Paris) 2013 Aug-Sep;29(8-9):693-5.
• 2013
  Casetti L, Martin-Lannerée S, Najjar I, Plo I, Augé S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I, Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells, Cancer Res. 2013 Apr;73(7):2052-8.
• 2011
  Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, Roger C, Dusanter-Fourt I, Varin-Blank N, Cao A, Metelev V, Baran-Marszak F, Fagard R, A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB, BMC Cell Biol. 2011 Apr;12:14.
• 2010
  Najjar I, Deglesne PA, Schischmanoff PO, Fabre EE, Boisson-Dupuis S, Nimmerjahn F, Bornkamm GW, Dusanter-Fourt I, Fagard R, STAT1-dependent IgG cell-surface expression in a human B cell line derived from a STAT1-deficient patient, J. Leukoc. Biol. 2010 Jun;87(6):1145-52.
• 2010
  Najjar I, Fagard R, STAT1 and pathogens, not a friendly relationship, Biochimie 2010 May;92(5):425-44.
• 2008
  Najjar I, Schischmanoff PO, Baran-Marszak F, Deglesne PA, Youlyouz-Marfak I, Pampin M, Feuillard J, Bornkamm GW, Chelbi-Alix MK, Fagard R, Novel function of STAT1beta in B cells: induction of cell death by a mechanism different from that of STAT1alpha, J. Leukoc. Biol. 2008 Dec;84(6):1604-12.
• 2005
  Najjar I, Baran-Marszak F, Le Clorennec C, Laguillier C, Schischmanoff O, Youlyouz-Marfak I, Schlee M, Bornkamm GW, Raphaël M, Feuillard J, Fagard R, Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells, J. Virol. 2005 Apr;79(8):4936-43.
• 2004
  Baran-Marszak F, Feuillard J, Najjar I, Le Clorennec C, Béchet JM, Dusanter-Fourt I, Bornkamm GW, Raphaël M, Fagard R, , Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells., Blood 2004 Oct; 104(8): 2475-83.